Clinical Trials Directory

Trials / Completed

CompletedNCT01781117

Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia

Prognostic Value of the Urinary Nerve Growth Factor (NGF) in the Patients With Benign Prostatic Hyperplasia (BPH) Who Undergo Holmium Laser Enucleation of the Prostate (HoLEP)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
184 (actual)
Sponsor
KYU-SUNG LEE · Academic / Other
Sex
Male
Age
50 Years – 80 Years
Healthy volunteers
Accepted

Summary

Persistent detrusor overactivity (DO) after transurethral prostatectomy results in symptomatic failure in more than one third of the patients. Storage symptoms are major complaints in the early postoperative period after Holmium Laser Enucleation of the Prostate (HoLEP). Levels of the urinary nerve growth factor (NGF), produced by bladder urothelium and smooth muscle, are increased in the patients with overactive bladder (OAB), and decreased after the OAB symptoms were improved. Also, urinary NGF levels are increased in patients with benign prostatic obstruction (BPO), but the changes of the NGF levels after relief of the BPO by the medical or surgical treatment have not been fully investigated. If the elevated urinary NGF levels are reduced after successful surgical treatment of BPO, measurement of urinary NGF could be a useful objective tool to assess the therapeutic outcomes of the operation. The aims of this study are to measure the urinary NGF levels in patients with BPO and to compare the results between the patients with detrusor overactivity (DO) and without detrusor overactivity (Non-DO), average 2 weeks before Holmium Laser Enucleation of the Prostate (HoLEP) procedure. After HoLEP, urinary NGF levels are rechecked at the periods of postoperative 3 months and 6 months, and compare changes between the two groups.

Detailed description

* Investigators are going to enroll age-matched control group and measure the urinary NGF levels as a baseline value (30 males). * Investigators are going to enroll BPO patients group (DO group 50 and Non-DO group 50 patients). * Administration of the anti-cholinergic agents was reported to decrease urinary NGF levels. Investigators are going to try to avoid the effect of anti-muscarinic drugs.

Conditions

Interventions

TypeNameDescription
PROCEDUREHolmium Laser Enucleation of the Prostate (HoLEP)Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.
DEVICEHolmium laser enucleation system and morcellatorHolmium laser enucleation and morcellation

Timeline

Start date
2013-02-01
Primary completion
2016-11-01
Completion
2017-01-01
First posted
2013-01-31
Last updated
2019-12-02

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01781117. Inclusion in this directory is not an endorsement.